Immunotherapy against invasive mold infections

Charalampos Antachopoulos1, Aspasia Katragkou, Emmanuel Roilides

  • 1Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece.

Immunotherapy
|December 14, 2011
PubMed

Insights

Invasive fungal infections pose a high risk for immunocompromised patients. Immunomodulatory treatments show promise but require more clinical evidence for widespread use against serious mold infections.

Area of Science:

  • Mycology
  • Immunology
  • Hematology

Background:

  • Invasive filamentous fungal infections (e.g., Aspergillus, Zygomycetes) lead to severe illness and death in immunocompromised individuals, including those with hematological malignancies and transplant recipients.
  • Standard antifungal therapies often yield poor outcomes, highlighting the critical role of immune restoration in treatment success.
  • Effective antifungal immunity relies on robust innate phagocytic functions and balanced pro-inflammatory and regulatory adaptive immune responses.

Purpose of the Study:

  • To review the role of immunomodulatory approaches as adjunctive treatments for invasive mold infections in immunocompromised patients.
  • To evaluate the current clinical evidence supporting the use of cytokines, T lymphocytes, and granulocyte transfusions in managing these serious fungal infections.

Main Methods:

  • Literature review of studies investigating immunomodulatory strategies for invasive fungal infections.
  • Analysis of in vitro and in vivo data on cytokine therapy, adoptive T cell transfer, and granulocyte transfusions.
  • Assessment of current clinical evidence and recommendations for immunomodulatory treatments.

Main Results:

  • Immunomodulatory strategies, including cytokine administration, pathogen-specific T lymphocyte transfer, and granulocyte transfusions, have been explored as adjunctive therapies.
  • Encouraging in vitro and in vivo data exist for these approaches.
  • However, current clinical evidence is insufficient to establish firm recommendations for their use in treating serious mold infections.

Conclusions:

  • Immune restoration is crucial for treating invasive fungal infections in immunocompromised patients.
  • While several immunomodulatory approaches show potential, robust clinical data is lacking.
  • Further clinical trials are necessary to determine the efficacy and safety of immunomodulatory modalities in managing serious mold infections.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...